Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system

Gynecological Endocrinology

Volumn 17, Issue 3, 2003, Pages 231-237

  Sills, E Scott ^a,d   Drews, C D ^b   Perloe, M ^a   Tucker, M J ^a   Kaplan, C R ^a   Palermo, G D ^c  

^a ATLANTA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Georgia Reproductive Specialists LLC   (United States)

Author keywords

Plasminogen Activator Inhibitor; Polycystic Ovary Syndrome; Thrombophilia

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGE DISTRIBUTION; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERINSULINISM; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL;

EID: 0037868307     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.17.3.231.237     Document Type: Article

References (25)

1. Sills ES, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol 2000;91:135-41
2. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Dunaif A, Givens JR, Haseltine F, et al. eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications, 1992:377-84
3. Hacihanefioglu B. Polycystic ovary syndrome nomenclature: chaos? Fertil Steril 2000;73:1261-2
4. Negri M, Shelban I, Arigliano PL, et al. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide, and plasminogen activator inhibitor-1. Am J Cardiol 1993;72:397-401
5. Lemne C, De Faire U. Elevation of plasminogen activator inhibitor-1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996;26:692-7
6. Henry, M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol 1998;18:84-91
7. Atiomo WU, Bates SA, Condon JE, et al. The plasminogen activator system in women with polycystic ovary, syndrome. Fertil Steril 1998;69:236-41
8. Sills ES, Genton MG, Perloe M, et al. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 2001;27:163-8
9. Burchfiel CM, Curb JD, Araki R, et al. Cardiovascular risk factors and hyperinsulinemia in elderly men: the Honolulu Heart Program. Ann Epidemiol 1996;6:490-7
10. Kluft C. Criteria and search for specific assays for active plasminogen activator inhibitor 1 (PAI-1) in plasma. J Int Fed Clin Chem Lab Med 2000;12:1-10
11. Sills ES, Levy DP, Wittkowski KM, et al. Preliminary experience with metformin treatment of polycystic ovary syndrome: reproductive outcomes among 20 consecutive patients. Fertil Steril 1999;72(Suppl. 1):S187-8
12. Declerck PJ, Collen D. Measurement of plasminogen activator inhibitor (PAI-1) in plasma with various monoclonal antibody-based enyzme-linked immunosorbent assays. Thromb Res 1990;Suppl. X:3-9
13. Vaughan D. Update on plasminogen activator-1. Can J Cardiol 1998;14(Suppl. D):14D-15D
14. Leonardsson G, Peng X-R, Liu K, et al. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci USA 1995;92:12446-50
15. Estelles A, Grancha S, Gilabert J, et al. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease. Am J Pathol 1996;149:1229-39
16. Vesce F, Scapoli C, Giovannini G, et al. Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. Obstet Gynecol 2001;97:404-8
17. Bellart J, Gilabert R, Fontcuberta J, et al. Coagulation and fibrinolysis parameters in normal parameters and in gestational diabetes. Am J Perinatol 1998;15:479-86
18. Glueck CJ, Phillips H, Cameron D, et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000;49:845-52
19. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-15
20. Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) levels in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45:623-9
21. Abbasi F, McLaughlin T, Lamendola C, et al. Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women. Arterioscler Thromb Vasc Biol 1999;19:2818-21
22. Banfi C, Eriksson P, Giandomenico G, et al. Transcriptional regulation of plasminogen activator inhibitor type-1 gene by insulin. Diabetes 2001;50:1522-30
23. Panahloo A, Yudkin JS. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. J Cardiovasc Risk 1997;4:91-9
24. Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation induction in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80
25. Sills ES, Perloe M, Levy DP, et al. Plasminogen activator inhibitor-1 levels, prothrombin G20210A and methyltetrahydrofolate reductase C677T gene polymorphism frequencies, and reproductive history: correlations with ultrasonographic ovarian morphology. Fertil Steril 2000;74(Suppl. 1):S13-14